Berberine ameliorates nonalcoholic fatty liver disease by decreasing the liver lipid content via reversing the abnormal expression of MTTP and LDLR

被引:29
作者
Chen, Ping [1 ]
Li, Yusheng [2 ]
Xiao, Li [2 ]
机构
[1] Shandong Med Coll, Dept Pharm, Affiliated Hosp, Linyi 276000, Shandong, Peoples R China
[2] Linyi Maternal & Child Hlth Care Hosp, Dept Pharm, 1 Qinghe South Rd, Linyi 276000, Shandong, Peoples R China
关键词
nonalcoholic fatty liver disease; berberine; microsomal triglyceride transfer protein; apolipoprotein B; low-density lipoprotein receptor; TRIGLYCERIDE TRANSFER PROTEIN; MESSENGER-RNA; APOLIPOPROTEIN; PREVALENCE; KINASE; DERIVATIVES; POPULATION; METABOLISM; SECRETION; MECHANISM;
D O I
10.3892/etm.2021.10543
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The global incidence of nonalcoholic fatty liver disease (NAFLD) is increasing. The present study explored the effect and mechanism of berberine (BBR) on NAFLD in rats. Thirty-five Sprague-Dawley rats were randomly divided into the control and NAFLD groups, which were fed a normal diet or high-fat diet, respectively, for 8 weeks. Hematoxylin and eosin staining was performed on liver tissues and establishment of the NAFLD model was confirmed by microscopy. NAFLD rats were subsequently randomly subdivided and treated with saline or BBR for 8 weeks. The liver wet weight of rats in each group was measured, the liver tissue structure was observed by microscopy, and alanine aminotransferase (ALT), aspartate aminotransferase (AST), total cholesterol (TC), triglyceride (TG), fasting blood glucose (FBG), low-density lipoprotein (LDL) and high-density lipoprotein (HDL) levels were detected using a semi-automatic biochemical detector. Reverse transcription-quantitative PCR and western blotting were performed to determine the mRNA and protein expression levels of microsomal triglyceride transfer protein (MTTP), apolipoprotein B and low-density lipoprotein receptor (LDLR). Compared with the control group, the liver wet weight of the NAFLD rats was higher; the liver showed obvious fatty degeneration and liver TG levels increased significantly, as did serum levels of ALT, AST, TC, TG, FBG, HDL and LDL, while expression of MTTP and LDLR significantly decreased. Compared with the saline-treated NAFLD rats, the BBR-treated rats had reduced liver wet weight, improved liver steatosis and a significant decrease in liver TG levels, while ALT, AST, TC, TG, and LDL serum levels significantly decreased and MTTP levels were significantly upregulated. In conclusion, BBR treatment ameliorated the fatty liver induced by a high-fat diet in rats. Furthermore, BBR reversed the abnormal expression of MTTP and LDLR in rats with high-fat diet induced-NAFLD. The present findings suggest that fatty liver could be improved by BBR administration, via reversing the abnormal expression of MTTP and LDLR and inhibiting lipid synthesis.
引用
收藏
页数:8
相关论文
共 49 条
[21]   Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background [J].
Kojima, S ;
Watanabe, N ;
Numata, M ;
Ogawa, T ;
Matsuzaki, S .
JOURNAL OF GASTROENTEROLOGY, 2003, 38 (10) :954-961
[22]   Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins [J].
Kong, WJ ;
Wei, J ;
Abidi, P ;
Lin, MH ;
Inaba, S ;
Li, C ;
Wang, YL ;
Wang, ZZ ;
Si, SY ;
Pan, HN ;
Wang, SK ;
Wu, JD ;
Wang, Y ;
Li, ZR ;
Liu, JW ;
Jiang, JD .
NATURE MEDICINE, 2004, 10 (12) :1344-1351
[23]   Comparison of anti-inflammatory effects of berberine, and its natural oxidative and reduced derivatives from Rhizoma Coptidis in vitro and in vivo [J].
Li, Cai-Lan ;
Tan, Li-Hua ;
Wang, Yong-Fu ;
Luo, Chao-Dan ;
Chen, Han-Bin ;
Lu, Qiang ;
Li, Yu-Cui ;
Yang, Xiao-Bo ;
Chen, Jian-Nan ;
Liu, Yu-Hong ;
Xie, Jian-Hui ;
Su, Zi-Ren .
PHYTOMEDICINE, 2019, 52 :272-283
[24]   Berberine induces miR-373 expression in hepatocytes to inactivate hepatic steatosis associated AKT-S6 kinase pathway [J].
Li, Chi Han ;
Tang, Shing Chun ;
Wong, Chi Hin ;
Wang, Yan ;
Jiang, Jian-dong ;
Chen, Yangchao .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2018, 825 :107-118
[25]   1H NMR-Based Metabolomics Coupled With Molecular Docking Reveal the Anti-Diabetic Effects and Potential Active Components ofBerberis vernaeon Type 2 Diabetic Rats [J].
Li, Qi ;
Zhao, Chengcheng ;
Zhang, Yunsen ;
Du, Huan ;
Xu, Tong ;
Xu, Xinmei ;
Zhang, Jing ;
Kuang, Tingting ;
Lai, Xianrong ;
Fan, Gang ;
Zhang, Yi .
FRONTIERS IN PHARMACOLOGY, 2020, 11
[26]   The Impacts of Herbal Medicines and Natural Products on Regulating the Hepatic Lipid Metabolism [J].
Li, Sha ;
Xu, Yu ;
Guo, Wei ;
Chen, Feiyu ;
Zhang, Cheng ;
Tan, Hor Yue ;
Wang, Ning ;
Feng, Yibin .
FRONTIERS IN PHARMACOLOGY, 2020, 11
[27]   Human antigen R: A potential therapeutic target for liver diseases [J].
Liu, Runping ;
Wu, Kaiyi ;
Li, Yajing ;
Sun, Rong ;
Li, Xiaojiaoyang .
PHARMACOLOGICAL RESEARCH, 2020, 155
[28]   Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method [J].
Livak, KJ ;
Schmittgen, TD .
METHODS, 2001, 25 (04) :402-408
[29]   Anti-inflammatory activity of berberine in non-alcoholic fatty liver disease via the Angptl2 pathway [J].
Lu, Zengsheng ;
He, Beihui ;
Chen, Zhiyun ;
Yan, Maoxiang ;
Wu, Liyan .
BMC IMMUNOLOGY, 2020, 21 (01)
[30]   Berberine Inhibits Nod-Like Receptor Family Pyrin Domain Containing 3 Inflammasome Activation and Pyroptosis in Nonalcoholic Steatohepatitis via the ROS/TXNIP Axis [J].
Mai, Weijian ;
Xu, Yangzhi ;
Xu, Jiahui ;
Zhao, Dan ;
Ye, Liangying ;
Yu, Ganxiang ;
Wang, Zhilei ;
Lu, Qianting ;
Lin, Jiaen ;
Yang, Tao ;
Gu, Chengxin ;
Liu, Shiming ;
Zhong, Yun ;
Yang, Hui .
FRONTIERS IN PHARMACOLOGY, 2020, 11